

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes **Pending:** The patent has been filed but not issued

Issued: The patent has been issued by the agency **Licensed:** The patent has been licensed to an entity, whether earning

royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

	2. Surr	ame (Last Name)		3. Date
Shayan	Ar	iwar		13 April 2023
Are you the corresponding author?	Yes	No		
Manuscript Title	11.00		1.91	
Tesla magnetic resonance in		patients lead to ps	eudo leptomen	ingeal enhancement in the brain
Manuscript Identifying Number (if you	0 0			
83852				
Section 2.				
The Work Under	Consider	ation for Publicatior	1	
				commercial, private foundation, etc.) for design, manuscript preparation, statistical
e there any relevant conflicts of inte	erest?	Yes No		
yes, please fill out the appropriate ir	nformation	below. If you have more	e than one entity p	ress the "ADD" button to add a row.
cess rows can be removed by press	ing the "X"	button.		
lame of Institution/Company		?	?	Comments
				×
				ADD
ection 3.				
ection 3. Relevant financia	al activitio	es outside the submi	tted work.	
Relevant Tinancia ace a check in the appropriate boxe compensation) with entities as des	es in the tab scribed in th	ole to indicate whether yne instructions. Use one	ou have financial ı line for each entity	r; add as many lines as you need by
Relevant financia ace a check in the appropriate boxe compensation) with entities as des cking the "Add +" box. You should i	es in the tak cribed in th report relat	ole to indicate whether yne instructions. Use one	ou have financial ı line for each entity	r; add as many lines as you need by
Relevant Tinancia ace a check in the appropriate boxe compensation) with entities as des cking the "Add +" box. You should i e there any relevant conflicts of inte	es in the tab cribed in the report relaterest?	ole to indicate whether yole instructions. Use one ionships that were pres	ou have financial ı line for each entity	r; add as many lines as you need by
Relevant Tinancia ace a check in the appropriate boxe compensation) with entities as des cking the "Add +" box. You should i e there any relevant conflicts of inte	es in the tab cribed in the report relaterest?	ole to indicate whether yole instructions. Use one ionships that were pres	ou have financial ı line for each entity	r; add as many lines as you need by
Relevant Tinancia ace a check in the appropriate boxe compensation) with entities as des cking the "Add +" box. You should i e there any relevant conflicts of inte yes, please fill out the appropriate in	es in the tab cribed in the report relaterest?	ole to indicate whether yole instructions. Use one ionships that were pres	vou have financial i line for each entity ent during the 36	r; add as many lines as you need by
Relevant financial lace a check in the appropriate boxe of compensation) with entities as destricting the "Add +" box. You should are there any relevant conflicts of integral yes, please fill out the appropriate in the app	es in the tab cribed in the report relaterest?	ole to indicate whether yole instructions. Use one ionships that were pres	vou have financial i line for each entity sent during the 36	r; add as many lines as you need by months prior to publication.

Section 4.	Intellectual	Property	Pateı	nts & Co _l	pyrights				
Do you have ar	ny patents, whet	her planned	d, pendir	ng or issue	ed, broadly r	relevant	to the work?	OYes ONo	
	l out the approp n be removed by				u have more	e than o	ne entity press	s the "ADD" button t	o add a row.
	?	Pending	?	?	?	?	Licensee?	Comments	
									×
									ADD
Section 5. Are there other	Relationsh	-			perceive to l	have inf	luenced, or th	at give the appearar	nce of
	uencing, what yo					nave iiii	idericed, or the	at give the appearar	ice of
Vos. the follo	owing relationsh	vins/conditie	ons/circu	ımstanco	aro procon	st (ovplai	in halaw):		
	ationships/cond	•			·	•		:t	
At the time of n	·	otance, jour	nals will	ask autho	ors to confirr	m and, if	f necessary, up	odate their disclosure	e statements.
Section 6.	Disclosure :	Statement	t						
Based on the al	oove disclosures	, this form v	vill autor	matically o	generate a c	disclosur	e statement, v	which will appear in	the box below
Generate D	isclosure State	ment							
Generate D	isciosare state								

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.